Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1

The Fc (fragment crystallizable) is a common structural region in immunoglobulin gamma (IgG) proteins, IgG-based multi-specific platforms, and Fc-fusion platform technologies. Changes in conformational stability, protein-protein interactions, and aggregation of NS0-produced human Fc1 were quantified experimentally as a function of pH (4 to 6) and temperature (30 to 77°C), using a combination of differential scanning calorimetry, laser light scattering, size-exclusion chromatography, and capillary electrophoresis. The Fc1 was O-glycosylated at position 3 (threonine), and confirmed to correspond to the intact IgG1 by comparison with Fc1 produced by cleavage of the parent IgG1. Changing the pH caused large effects for thermal unfolding transitions, but it caused surprisingly smaller effects for electrostatic protein-protein interactions. The aggregation behavior was qualitatively similar across different solution conditions, with soluble dimers and larger oligomers formed in most cases. Aggregation rates spanned approximately 5 orders of magnitude and could be divided into 2 regimes: (i) Arrhenius, unfolding-limited aggregation at temperatures near or above the midpoint-unfolding temperature of the CH2 domain; (ii) a non-Arrhenius regime at lower temperatures, presumably as a result of the temperature dependence of the unfolding enthalpy for the CH2 domain. The non-Arrhenius regime was most pronounced for lower temperatures. Together with the weak protein-protein repulsions, these highlight challenges that are expected for maintaining long-term stability of biotechnology products that are based on human Fc constructs.

[1]  Ian Kimber,et al.  Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.

[2]  P. Souillac Biophysical characterization of insoluble aggregates of a multi-domain protein: an insight into the role of the various domains. , 2005, Journal of pharmaceutical sciences.

[3]  Yi Li,et al.  Reexamining protein-protein and protein-solvent interactions from Kirkwood-Buff analysis of light scattering in multi-component solutions. , 2011, The Journal of chemical physics.

[4]  R. Kontermann Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.

[5]  Christopher J Roberts,et al.  Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. , 2003, Journal of pharmaceutical sciences.

[6]  C. Roberts,et al.  Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. , 2011, Journal of pharmaceutical sciences.

[7]  Wei Wang,et al.  Non-Arrhenius Protein Aggregation , 2013, The AAPS Journal.

[8]  Vishal Nashine,et al.  Significance of Unfolding Thermodynamics for Predicting Aggregation Kinetics: A Case Study on High Concentration Solutions of a Multi-Domain Protein , 2013, Pharmaceutical Research.

[9]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.

[10]  X. Zhong,et al.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications , 2013, International journal of cell biology.

[11]  Christopher J Roberts,et al.  A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. , 2007, The journal of physical chemistry. B.

[12]  T. Irimura,et al.  O-glycosylation in hinge region of mouse immunoglobulin G2b. , 1994, The Journal of biological chemistry.

[13]  I. Krull,et al.  Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. , 1999, Analytical biochemistry.

[14]  Christopher J Roberts,et al.  Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. , 2011, Journal of pharmaceutical sciences.

[15]  William L. Smith,et al.  Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. , 2008, Trends in biochemical sciences.

[16]  H. Gadgil,et al.  Elucidation of Acid-induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc , 2011, The Journal of Biological Chemistry.

[17]  Peter M Bowers,et al.  An integrated approach to extreme thermostabilization and affinity maturation of an antibody. , 2013, Protein engineering, design & selection : PEDS.

[18]  Vincenzo Martorana,et al.  Protein–Protein Interactions in Dilute to Concentrated Solutions: α-Chymotrypsinogen in Acidic Conditions , 2014, The journal of physical chemistry. B.

[19]  Zuben E Sauna,et al.  Fc fusion as a platform technology: potential for modulating immunogenicity. , 2015, Trends in biotechnology.

[20]  Jianping Zhou,et al.  Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. , 2010, Journal of pharmaceutical sciences.

[21]  James L Cole,et al.  Analytical ultracentrifugation: sedimentation velocity and sedimentation equilibrium. , 2008, Methods in cell biology.

[22]  Arthur J. Rowe,et al.  Analytical ultracentrifugation in biochemistry and polymer science , 1992 .

[23]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[24]  Edward J. Wood,et al.  Biochemistry (3rd ed.) , 2004 .

[25]  A. Robinson,et al.  Competing aggregation pathways for monoclonal antibodies , 2014, FEBS letters.

[26]  Malgorzata B. Tracka,et al.  The role of electrostatics in protein-protein interactions of a monoclonal antibody. , 2014, Molecular pharmaceutics.

[27]  Bruce A Kerwin,et al.  Specific-ion effects on the aggregation mechanisms and protein-protein interactions for anti-streptavidin immunoglobulin gamma-1. , 2015, The journal of physical chemistry. B.

[28]  Lai-Xi Wang,et al.  Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. , 2014, Journal of molecular biology.

[29]  P. Brown,et al.  Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. , 2006, Biophysical journal.

[30]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[31]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[32]  Janice M Reichert,et al.  Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies , 2011, mAbs.

[33]  Naresh Chennamsetty,et al.  Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. , 2011, Journal of pharmaceutical sciences.

[34]  C. Roberts,et al.  Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. , 2007, Biochemistry.

[35]  M. A. Cayless Statistical Mechanics (2nd edn) , 1977 .

[36]  William F. Weiss,et al.  Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. , 2009, Journal of pharmaceutical sciences.

[37]  Babatunde A. Ogunnaike,et al.  Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. , 2010, Journal of pharmaceutical sciences.

[38]  Christopher J Roberts,et al.  Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. , 2013, Biophysical chemistry.

[39]  S. Demarest,et al.  Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences. , 2004, Journal of molecular biology.

[40]  S. Demarest,et al.  A broad range of Fab stabilities within a host of therapeutic IgGs. , 2007, Biochemical and biophysical research communications.

[41]  E. Reynolds,et al.  Rules relating electrophoretic mobility, charge and molecular size of peptides and proteins. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[42]  M. Fanger,et al.  Bispecific antibodies. , 1992, Critical reviews in immunology.

[43]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[44]  J. Dumont,et al.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.

[45]  P. Carter,et al.  Introduction to current and future protein therapeutics: a protein engineering perspective. , 2011, Experimental cell research.

[46]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[47]  C. Roberts Kinetics of Irreversible Protein Aggregation: Analysis of Extended Lumry−Eyring Models and Implications for Predicting Protein Shelf Life , 2003 .

[48]  Saurabh Aggarwal,et al.  What's fueling the biotech engine? , 2007, Nature Biotechnology.

[49]  A. Vermeer,et al.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.

[50]  C. King,et al.  Extraction chemistry of fermentation product carboxylic acids. , 1986, Biotechnology and bioengineering.

[51]  J. Wyman,et al.  Biochemistry and Geochemistry , 1958 .

[52]  Christopher J Roberts,et al.  Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.

[53]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[54]  Abraham M Lenhoff,et al.  Direct measurement of protein osmotic second virial cross coefficients by cross‐interaction chromatography , 2004, Protein science : a publication of the Protein Society.

[55]  Christopher J Roberts,et al.  Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. , 2010, Journal of pharmaceutical sciences.

[56]  Massimo Morbidelli,et al.  On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution. , 2012, Biophysical chemistry.

[57]  Sandeep Kumar,et al.  Identification and Impact of Aggregation‐Prone Regions in Proteins and Therapeutic Monoclonal Antibodies , 2010 .

[58]  Michael F. Drenski,et al.  Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering. , 2013, Analytical biochemistry.

[59]  Yelena Lyubarskaya,et al.  Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity. , 2006, Analytical biochemistry.

[60]  Arieh Ben-Naim,et al.  Statistical Thermodynamics for Chemists and Biochemists , 1992, Springer US.

[61]  Peter Schuck,et al.  Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. , 2002, Biophysical journal.

[62]  D. C. Henry The cataphoresis of suspended particles. Part I.—The equation of cataphoresis , 1931 .

[63]  C. Roberts,et al.  Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. , 2009, The journal of physical chemistry. B.